


Not Exhaustive; companies only
Position within Phase does not imply proximity to next phase
Position represents highest development stage for each asset

As of November 21st, 2023

Legend

Target / Payload	MMAE	DXd	Other	Undisclosed
Other				
HER2				
BCMA				



Heidelberg Pharma  @andrewpannu
Andrew Pannu
Powered By Sleuth Insights

- (1) FDA issued CRL in May 2023
- (2) FDA pulled from market following DREAMM-3 trial failure (2022)
- (3) FDA paused study due to safety concerns
- (4) Withdrawn in 2010; reapproved in 2017
- (5) Partnered with Pierre Fabre